How Much Should Gardasil Cost?

Merck could cut the price of its new vaccine by 90% and still do very well.

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

A sneaky virus has infected 20 million Americans. For most, it's just an inconvenience, causing unattractive lesions. But for some, the infection leads to cancer, killing 250,000 people worldwide and costing billions in medical expenses every year. The vast majority of people who develop the cancer live in low-income countries, where it has become the most common type of cancer in women. After years of research, a company has released a vaccine that prevents nearly 100% of infections by the four forms of the virus that cause most of its problems. The question is: How much should such a life-saving vaccine cost?

Most of you probably realize that I'm talking about Gardasil, which Merck developed and the US Food and Drug Administration approved last year. The vaccine targets human papillomavirus (HPV), which can cause genital warts and, eventually, cervical cancer. Given the impact HPV has on sexually active people worldwide, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Glenn McGee

    This person does not yet have a bio.

Published In

Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development